Zydus launches reusable multi-dose Semaglutide pen for diabetes and obesity in India

An announcement from Zydus Lifesciences Limited ( (IN:ZYDUSLIFE) ) is now available.

Zydus Lifesciences has launched Semaglutide Injection in India under the brand names SEMAGLYN, MASHEMA and ALTERME following patent expiry, targeting Type 2 diabetes and obesity. Approved by the Drug Controller General of India, the therapy is positioned for a wide patient base amid rapidly rising incidence of both conditions across the country.

Differentiating itself from existing options, Zydus is offering the drug in a prefilled 15mg/3ml cartridge used with an innovative reusable multi-dose pen device to which it holds exclusive rights. The device allows clinicians and patients to adjust various dose strengths from a single pen, aiming to improve adherence and convenience while cutting overall treatment costs to around Rs. 2,200 per month.

The launch directly addresses India’s worsening metabolic health crisis, where tens of millions live with diabetes and obesity prevalence has nearly doubled among women and more than doubled among men. By coupling a GLP-1 therapy with a cost-efficient, patient-friendly delivery system manufactured at its Ahmedabad biotech facility, Zydus strengthens its position in the high-growth diabetes and obesity segment and could expand access to advanced treatments for a broad population.

More about Zydus Lifesciences Limited

Zydus Lifesciences Limited is an innovation-led global life sciences company focused on pharmaceuticals and biologics. The company develops and markets treatments across chronic disease areas such as diabetes and obesity, with a growing presence in India’s large and expanding metabolic disorders market.

Average Trading Volume: 26,089

Technical Sentiment Signal: Hold

Current Market Cap: 881.8B INR

Find detailed analytics on ZYDUSLIFE stock on TipRanks’ Stock Analysis page.